NR1H4 and metabolic disease: To examine the effect on metabolic disorders, GUDCA (5) was administered (50 mg/kg/d) for 4 weeks and showed therapeutic effects in reversing metabolic disorders in established HFD mice through intestinal FXR antagonism, increased metabolic rate, and GLP1 production [18].